文献速递肺结节与肺癌

YES1驱动肺癌生长进展并预测达沙替尼敏感性

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

该研究评估YES1基因改变作为NSCLC治疗靶点及达沙替尼疗效预测标志物,采用体内模型、患者来源异种移植及CRISPR/Cas9基因敲除等方法,发现YES1对肺癌发生至关重要,其扩增细胞系和PDX模型对达沙替尼高度敏感,高YES1蛋白表达为不良预后独立预测因子。

要点

  • YES1基因扩增可作为达沙替尼疗效分层生物标志物。
  • CRISPR/Cas9敲除YES1显著减少肿瘤生长和转移。
  • 高YES1蛋白表达是肺癌患者不良预后的独立预测因子。

核心结论

  • YES1是肺癌有前景的治疗靶点,支持以YES1状态为预测标志物临床评估达沙替尼。

研究设计与样本

  • 研究采用NSCLC体内模型、转移模型和患者来源异种移植评估YES1功能意义。
  • 通过药理学和CRISPR/Cas9基因敲除评估YES1缺失效果,并进行体外信号、生存和侵袭功能实验。
  • 在临床样本中评估YES1改变与预后的关联。

主要发现

  • YES1对NSCLC癌变至关重要,其过表达在临床前体内模型中诱导转移扩散。
  • CRISPR/Cas9技术敲除YES1显著减少肿瘤生长和转移。
  • YES1效应主要由mTOR信号驱动。
  • YES1基因扩增的细胞系和患者来源异种移植模型对SFK抑制剂达沙替尼高度敏感。
  • 高YES1蛋白表达是肺癌患者不良预后的独立预测因子。

临床怎么用

  • YES1状态可作为达沙替尼治疗NSCLC患者的分层生物标志物。
  • 高YES1蛋白表达提示肺癌患者预后不良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non-small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer.Objectives: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) genetic alteration as a therapeutic target and predictive biomarker of response to dasatinib in NSCLC.Methods: Functional significance was evaluated by in vivo models of NSCLC and metastasis and patient-derived xenografts. The efficacy of pharmacological and genetic (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also evaluated. In vitro functional assays for signaling, survival, and invasion were also performed. The association between YES1 alterations and prognosis was evaluated in clinical samples.Measurements and Main Results: We demonstrated that YES1 is essential for NSCLC carcinogenesis. Furthermore, YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. YES1 effects were mainly driven by mTOR (mammalian target of rapamycin) signaling. Interestingly, cell lines and patient-derived xenograft models with YES1 gene amplifications presented a high sensitivity to dasatinib, an SFK inhibitor, pointing out YES1 status as a stratification biomarker for dasatinib response. Moreover, high YES1 protein expression was an independent predictor for poor prognosis in patients with lung cancer.Conclusions: YES1 is a promising therapeutic target in lung cancer. Our results provide support for the clinical evaluation of dasatinib treatment in a selected subset of patients using YES1 status as predictive biomarker for therapy.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Garmendia I, Pajares MJ, Hermida-Prado F, et al. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Respir Crit Care Med. 2019. PMID: 31166114. doi:10.1164/rccm.201807-1292OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。